In animal studies, ORC-13661 provided highly significant protection of hearing in rats exposed to high doses of aminoglycoside antibiotics, a common cause of human hearing loss.
Funding for the preclinical development was obtained through grants from the National Institutes of Health, including a USD2.1 m grant from National Institute Of Allergy And Infectious Diseases.
Privately held Oricula is introducing medications to protect hearing and balance from the damaging effects of medications and aging.
The company is commercializing research conducted at the University of Washington and the Fred Hutchinson Cancer Research Center and holds an exclusive license to the resulting intellectual property.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial